Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Avg
|
New words:
Abbott, ABECB, absorbed, accrual, adult, advertising, aeruginosa, AF, againstC, againstH, albicansand, alleging, America, andC, andin, andleprae, Andorra, annum, arena, article, asC, Asia, asS, assist, atypical, auction, Augmentin, Austria, Avelox, azithromycin, back, bacteriological, bacteriumClostridium, baumannii, Belgium, Biaxin, bid, billionin, bioequivalence, bothin, British, broaden, broader, brought, buy, byH, California, Canadian, CAP, carboxylic, category, cefuroxime, cGMP, Chemistry, choice, Cipro, ciprofloxacin, claim, Clarinex, clarithromycin, Claritin, CMC, Coast, competitor, complementary, composed, conclusion, Concurrent, constituted, cooperating, cough, Court, cytoplasmic, david, debtor, deformylase, degree, Delaware, Denmark, difficilecan, difficulty, diligently, Division, domain, driven, dual, duration, earliest, East, education, efficient, electronically, element, Eli, empiric, endpoint, England, ensure, enumerated, enzyme, Europe, European, evenly, exacerbation, excellent, exhausted, explore, exploring, FACTIVE, fail, favorable, FIN, Finland, fluoroquinolone, fold, Fourteen, Francisco, fueled, fulfill, gatifloxacin, gemifloxacin, genesoft, Germany, GlaxoSmithKline, goodwill, Greece, gyrase, hand, heavily, hydroxamic, Iceland, ImmuCell, IMS, incremental, indefinitely, Induced, influenzaeandMoraxella, ingredient, inherent, inhibitor, inin, inspection, insurance, intangible, inThe, investor, Ireland, issuable, Italy, IV, jr, Ketek, ketolide, Kingdom, Korea, launch, led, left, Levaquin, levofloxacin, LG, Lilly, Longitudinal, lowin, Luxembourg, mainstay, mandatory, margin, Marino, marketplace, Martin, MDRSP, Medicine, mesylate, metalloenzyme, mild, mix, moderate, Monaco, moving, moxifloxacin, Mycoplasma, Nalidixic, nanobinder, Nexium, nonpublic, norbert, North, Norway, nosocomial, Nox, ofClostridium, ofH, older, open, ourH, outcome, outplacement, overgrowth, owed, owner, pace, paragraph, Pasteur, PathoGenome, PathoGenomeTM, PDF, penetrate, peptide, Pharma, Pharmco, pivotal, plaintiff, plant, pneumoniaedouble, pneumoniaeresistant, pneumoniaeshowing, pneumoniaethat, Portugal, possession, potassium, potentin, premise, Prilosec, promissory, promotion, proportion, proximate, PRSP, Puerto, pyloriand, pyrrolidine, quinoline, quinolone, rash, ratio, reardon, recall, receipt, recommend, recommended, recordkeeping, recovered, redeemable, redeemed, redemption, reduction, reexamination, reexamined, regained, regimen, remedial, rent, Republic, reserved, retirement, retroactively, Rico, riedel, San, satisfaction, SB, seizure, sellin, settlement, shelf, Shoreline, singer, skilled, Society, sought, South, Spain, stone, straight, substance, substituent, summarized, summer, suppression, suspension, Sweden, Switzerland, Tequin, territory, tid, Tinactin, toAcinetobacter, toKlebsiella, toMycobacterium, topoisomerase, Trademark, treatClostridium, trimethoprim, trovafloxacin, unable, uncontrolled, Union, unissued, unmet, vacant, vacate, Vanconin, Vatican, vernon, VIE, vitroactivity, vitropotential, waiver, warning, weakened, website, West, william, withC, withH, yearly, Yesx, Zithromax
Removed:
acceptable, adversely, analyzing, animal, applying, assay, assemble, assure, attract, authorization, automation, awarded, biochemical, Candida, capability, challenged, characterize, charged, collaborator, commonly, Consent, coverage, create, delay, demonstrating, depreciated, determination, directed, directly, discovering, downstream, dozen, enabled, error, establishment, expended, experienced, finance, Fleet, fluctuate, fluctuated, focusing, fragment, fully, function, fungi, furnished, furniture, genotyping, Independent, inherited, integrated, introduced, isolate, joint, level, library, limit, linkage, LLP, maintaining, managed, maximize, maximum, measurement, molecule, monthly, narrow, narrowed, natural, negotiation, newly, NIH, noncash, nonexclusive, nonqualified, occurring, organized, overseeing, partial, payroll, plough, practice, premature, production, Professional, profiling, proposed, protected, raw, recombinant, relevance, relocation, repaid, representing, requirement, revision, scheduled, select, situation, small, software, speed, staph, statutory, step, suitable, Sumitomo, supplemental, throughput, unclear, undergoing, utility, utilize, vast, vivo, volatility, Working
Filing tables
Filing exhibits
- 10-K Annual report
- 23.1 Consent of Ernst & Young LLP Independent Public Accountants
- 31.1 Certification of the CEO Pursuant to Section 302 of the Sarbanes-oxley Act
- 31.2 Certification of the CFO Pursuant to Section 302 of the Sarbanes-oxley Act
- 32.1 Certification of the CEO Pursuant to Section 906 of the Sarbanes-oxley Act
- 32.2 Certification of the CFO Pursuant to Section 906 of the Sarbanes-oxley Act
- 99.1 Risk Factors
OSCI similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT ACCOUNTANTS
We consent to the incorporation by reference in the Registration Statements (File Nos. 2-77846, 2-81123, 2-95446, 33-12633, 33-27885, 0-10824, 33-45432, 33-75136, 333-15935, 333-49069, 333-30920, 333-39390, 333-92951, 333-32614, 333-58274 and 333-112810,333-106563, and 333-97139) of our report dated February 13, 2004, with respect to the consolidated financial statements of Genome Therapeutics, Corp. included in the Annual Report (Form 10-K) for the year ended December 31, 2003.
/s/ ERNST & YOUNG LLP
Boston, Massachusetts
March 3, 2004